Utility Outcome Measures for the Treatment of Ameloblastomas during Childhood.

Our objective was to determine the potential impact of the surgical treatment of ameloblastoma in children through validated health state utility outcome measures. METHODS: A survey-based preference health utility assessment using the visual analog scale, time trade-off, and standard gamble methods was undertaken among a general population sample. Quality-adjusted life years were derived from these measures. A one-way ANOVA was used for statistical analysis, with a mean (P) value of 0.05 considered significant. Demographic parameters were individually assessed as possible predictors of each utility score. RESULTS: In total, 86 participants took part in this study, with a mean age of 29.9 years. Greater utility scores were observed among participants reporting no religious beliefs (P = 0.025, t = 2.28). No other demographic parameters showed statistically significant prediction of utility score. From the mean utility scores (± SD) (visual analog scale = 0.60 ± 0.17; time trade-off = 0.65 ± 0.22; standard gamble = 0.64 ± 0.20), a gain of 30.0, 32.3, and 32.1 quality-adjusted life years may be derived, respectively. All utility outcome measures suggested that an ameloblastoma during childhood is perceived as more burdensome than several debilitating conditions, such as cleft lip and palate. CONCLUSIONS: To attain perfect health, participants would theoretically undergo surgical treatment of an ameloblastoma during childhood, with willingness to trade off 28.2 years of life and accepting a 35.7% risk of death. The objective assessment of the perceived burden of an ameloblastoma affliction during childhood may inspire cost-utility or cost-effectiveness analyses at broader societal levels.